rss
Br J Ophthalmol 97:236-237 doi:10.1136/bjophthalmol-2012-302725
  • PostScript
  • Letters

Availability of anti-VEGF agents for the management of advanced diabetic retinopathy in the NHS

  1. Hadi Zambarakji
  1. The Eye Treatment Centre, Barts Health NHS Trust, Whipps Cross University Hospital, London, UK
  1. Correspondence to Dr Adeela Malik, The Eye Treatment Centre, Barts Health NHS Trust, Whipps Cross University Hospital, Whipps Cross Road, London E11 1NR, UK; adeela15malik{at}gmail.com
  • Accepted 18 October 2012
  • Published Online First 29 November 2012

The anti-vascular endothelial growth factor (anti-VEGF) drug Bevacizumab (Avastin Genentech Inc. (Roche Group), San Francisco, California, USA) has been in circulation for several years within the ophthalmic community. Numerous studies have reported clinical outcomes of Bevacizumab in the context of proliferative diabetic retinopathy (PDR)1–4 and neovascular glaucoma. These, including a comprehensive review5 and a meta-analysis,6 have all reported favourable clinical outcomes. Studies therefore confirm that Bevacizumab reduces the risk of haemorrhage, reduces the need for endodiathermy, facilitates surgery and reduces surgical time if administered days prior to vitrectomy surgery for PDR. Bevacizumab also reduces retinal neovascularisation and/or iris neovascularisation in patients with rubeotic glaucoma secondary to advanced PDR when used …

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article